GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unipharma Co Ltd (ROCO:6621) » Definitions » ROE % Adjusted to Book Value

Unipharma Co (ROCO:6621) ROE % Adjusted to Book Value : -5.88% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Unipharma Co ROE % Adjusted to Book Value?

Unipharma Co's ROE % for the quarter that ended in Dec. 2024 was -10.17%. Unipharma Co's PB Ratio for the quarter that ended in Dec. 2024 was 1.73. Unipharma Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -5.88%.


Unipharma Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Unipharma Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unipharma Co ROE % Adjusted to Book Value Chart

Unipharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.72 -16.06 -1.18 -4.21 -4.80

Unipharma Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.25 -1.49 -6.37 -3.33 -5.88

Competitive Comparison of Unipharma Co's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unipharma Co's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Unipharma Co's ROE % Adjusted to Book Value falls into.


;
;

Unipharma Co ROE % Adjusted to Book Value Calculation

Unipharma Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8.31% / 1.73
=-4.80%

Unipharma Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-10.17% / 1.73
=-5.88%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Unipharma Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Unipharma Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Unipharma Co Business Description

Traded in Other Exchanges
N/A
Address
Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.

Unipharma Co Headlines

No Headlines